News Orders & Deals Ortin Global Limited: Parveen Satija Announces Open Offer for 26% Stake at ₹14.65 Per ShareOrtin Global Limited: Parveen Satija Announces Open Offer for 26% Stake at ₹14.65 Per Share
Mr. Parveen Satija has announced an open offer to acquire 21,14,162 equity shares (26% voting capital) of Ortin Global Limited at ₹14.65 per share, with total consideration of ₹3,09,72,473.30. The offer follows a Share Purchase Agreement with promoter sellers for 1,00,300 shares (1.23% stake). The acquirer has established financial arrangements including an escrow deposit of ₹80,52,850 with Axis Bank Limited and will implement the offer through BSE's acquisition window mechanism from April 10-24, 2026.
*this image is generated using AI for illustrative purposes only.
Ortin Global Limited has received a detailed public statement from Mr. Parveen Satija announcing an open offer to acquire a significant stake in the pharmaceutical and chemicals company. The announcement, made through manager Rarever Financial Advisors Private Limited, outlines the acquirer's intention to purchase 21,14,162 equity shares representing 26% of the company's voting capital.
Open Offer Details
The open offer presents a comprehensive acquisition proposal structured under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Mr. Parveen Satija, aged 55 years and residing in Delhi, has positioned himself to acquire control of the Target Company through this strategic transaction.
| Parameter | Details |
|---|---|
| Offer Size | 21,14,162 equity shares |
| Voting Capital Percentage | 26.00% |
| Offer Price | ₹14.65 per share |
| Face Value | ₹10.00 per share |
| Total Consideration | ₹3,09,72,473.30 |
Background Transaction
The open offer stems from a Share Purchase Agreement executed on February 10, 2026, between the acquirer and four promoter sellers. This underlying transaction involves the acquisition of 1,00,300 equity shares representing 1.23% of the existing paid-up capital.
| Promoter Seller | Pre-Transaction Shares | Percentage | Post-Transaction |
|---|---|---|---|
| Murali Krishna Murthy Sanka | 17,844 | 0.22% | Nil |
| Venkata Sujatha Sanka | 21,944 | 0.27% | Nil |
| Lakshmi Sravani Dasari | 20,000 | 0.24% | Nil |
| Sanka Tandav Krishna | 40,512 | 0.50% | Nil |
| Total | 1,00,300 | 1.23% | Nil |
The aggregate consideration for the underlying Share Purchase Agreement amounts to ₹14,69,395, with all promoter sellers transferring their complete holdings to the acquirer.
Acquirer Profile and Financial Arrangements
Mr. Parveen Satija brings over 20 years of business experience and holds a Bachelor of Commerce degree from Punjab University, Chandigarh. He currently serves as Director of Samsung Electro Product Private Limited and has a certified net worth of ₹8.54 crores as of January 27, 2026.
The acquirer has established robust financial arrangements to support the open offer:
- Escrow Account: Opened with Axis Bank Limited under the name "PARVEEN SATIJA - OPEN OFFER ESCROW ACCOUNT"
- Escrow Deposit: ₹80,52,850 (more than 25% of total consideration)
- Funding Source: Internal resources without external borrowings
- Certification: Financial adequacy certified by M/s. Jay M. Shah & Co., Chartered Accountants
Offer Price Determination
The offer price of ₹14.65 per equity share has been determined in accordance with Regulations 8(1) and 8(2) of SEBI (SAST) Regulations, 2011. The price represents the highest among various parameters considered:
| Price Parameter | Amount (₹) |
|---|---|
| Highest negotiated price under agreement | 14.65 |
| Volume-weighted average market price (60 trading days) | 14.64 |
| Other acquisition prices | Not Applicable |
The equity shares of Ortin Global Limited are frequently traded on both BSE (Script Code: 539287) and NSE (Script Symbol: ORTINGLOBE), with annualized trading turnover of 50.67% on NSE and 19.63% on BSE during the twelve months prior to the public announcement.
Company Overview and Financial Performance
Ortin Global Limited, originally incorporated as Ortin Laboratories Private Limited in 1986, operates in the pharmaceutical and chemicals sector. The company manufactures and trades in various chemicals, medicines, food preparations, and healthcare products.
Recent financial performance shows:
| Period | Total Income (₹ Lakhs) | Net Profit/Loss (₹ Lakhs) | EPS (₹) |
|---|---|---|---|
| Nine months ended Dec 31, 2025 | 10.72 | (73.11) | (0.90) |
| FY 2025 | 38.35 | (84.64) | (1.04) |
| FY 2024 | 228.49 | (804.10) | (9.89) |
| FY 2023 | 606.23 | (9.36) | (0.12) |
Implementation Timeline
The open offer follows a structured timeline with key milestones:
- Public Announcement: February 10, 2026
- Detailed Public Statement: February 17, 2026
- Tendering Period: April 10, 2026 to April 24, 2026
- Payment Completion: By May 11, 2026
- Final Report Filing: May 18, 2026
BSE Limited serves as the designated stock exchange for tendering equity shares, with M/s. South Gujarat Shares & Sharebrokers Limited appointed as the buying broker. The offer will be implemented through the stock exchange's acquisition window mechanism.
Strategic Implications
Upon completion of the open offer, assuming full acceptance, Mr. Parveen Satija will hold 22,14,462 equity shares representing 27.23% of the paid-up equity share capital. The acquirer has stated intentions to expand business operations and drive the next phase of growth for the Target Company.
The transaction may result in the public shareholding falling below the minimum 25% requirement, necessitating steps to restore compliance with SEBI (LODR) Regulations within prescribed timelines. All existing promoter sellers will cease to be members of the promoter group following the completion of the underlying transaction.
Historical Stock Returns for Ortin Global
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.98% | +27.50% | +43.75% | +55.92% | +65.88% | -41.66% |
19
